Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress

Eur J Med Chem. 2022 Aug 5:238:114464. doi: 10.1016/j.ejmech.2022.114464.

Zhipei Sang ¹, Keren Wang ², Jianghong Dong ³, Lei Tang ⁴

Affiliations

1 State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, China; School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, 570228, China. Electronic address: sangzhipei@126.com.
2 College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, 473061, China.
3 College of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, 330004, China.
4 State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, China. Electronic address: tl1974@163.com.

PMID: 35635955 DOI: 10.1016/j.ejmech.2022.114464

Abstract

Alzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting over 30 million people globally. Currently, no effective treatment is available due to multiple factors involved in the progression of AD. Given that the numerous AD-related targets in the disease network, the multi-target-directed ligands (MTDLs) strategy are considered as the promising strategy to treat AD. Herein, the multi-target compounds with/without ChEs are in clinical and in progress are reviewed. To further characterize the drug-likeness, and ADME properties are calculated using the Qikprop. This review will provide highlights for the treatment of AD.

Keywords

ADME property; Alzheimer's disease; Multi-target-directed ligands.

Name
Email *

	Sorry, but the email address you supplied was invalid.